82 results
Keyword Loratadine Remove keyword
-
List item
Referral: Loratadine
loratadine, Article 31 referrals
Status: European Commission final decision, opinion/position date: 21/11/2003, EC decision date: 28/04/2004, Last updated: 14/07/2004Loratadine … Commission final decision Overview Loratadine is an anti-histamine compound … the H-1 antagonist group. Loratadine has been authorised nationally … -
List item
Referral: Loratadine Sandoz 10
loratadine, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 29/05/2009, EC decision date: 06/08/2009, Last updated: 12/12/2009Loratadine Sandoz 10 … authorisation of the medicine Loratadine Sandoz 10. The Agency's Committee … concluded that the benefits of Loratadine Sandoz 10 do not outweigh … -
List item
Referral: Loraxin
loratadine, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 18/10/2012, EC decision date: 20/12/2012, Last updated: 28/02/2013active substance in Loraxin, loratadine, is an antihistamine. It works … Loraxin and associated names (loratadine, 10 mg tablets) PDF icon … Loraxin and associated names (loratadine, 10 mg tablets) Outcome … -
List item
Referral: Loratadine and pseudoephedrine
loratadine, pseudoephedrine, Article 31 referrals
Status: European Commission final decision, opinion/position date: 21/11/2003, EC decision date: 28/04/2004, Last updated: 14/07/2004Loratadine and pseudoephedrine … Commission final decision Overview Loratadine is an anti-histamine compound … terminals. The combination of loratadine and pseudoephedrine has been … -
List item
Human medicine European public assessment report (EPAR): Neoclarityn
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 15/01/2001, Revision: 45, Authorised, Last updated: 15/12/2022allergic) to desloratadine, loratadine or any of the other ingredients … allergic) to desloratadine, loratadine or any of the other ingredients … -
List item
Human medicine European public assessment report (EPAR): Azomyr
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 15/01/2001, Revision: 51, Authorised, Last updated: 15/12/2022allergic) to desloratadine, loratadine or any of the other ingredients … allergic) to desloratadine, loratadine or any of the other ingredients … -
List item
Human medicine European public assessment report (EPAR): Aerius
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 15/01/2001, Revision: 49, Authorised, Last updated: 15/12/2022allergic) to desloratadine, loratadine or any of the other ingredients … allergic) to desloratadine, loratadine or any of the other ingredients … -
List item
Human medicine European public assessment report (EPAR): Aerinaze
desloratadine, pseudophedrine sulfate, Rhinitis, Allergic, Seasonal
Date of authorisation: 30/07/2007, Revision: 22, Authorised, Last updated: 07/12/2022to adrenergic agents or to loratadine (another medicine used to … to adrenergic agents or to loratadine (another medicine used … -
List item
National expert: Karl-Friedrich Lukat, Federal Institute for Drugs and Medical Devices (updated)
- Declaration of interests - 79.82 KB | PDF
- Curriculum Vitae - 20.88 KB | PDF
Vergleich mit Azelastin 1 * 4 mg, Loratadin 1 * 2 mg und Plazebo im Hautmodell. [Antihistaministic … Comparison to azelastine 1 * 4 mg, loratadine 1 * 2 mg, and placebo by … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,22-25 September 2008
CHMP, Last updated: 25/09/2008population should be included. Loratadine Sandoz 10, 10 mg tablets loratadine), from Sandoz BV, intended … -
List item
National expert: Dimitrios Dimas, National Organization for Medicines (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 18.28 KB | PDF
Rekkas. "In vitro evaluation of Loratadine permeation through human … -
List item
Human medicine European public assessment report (EPAR): Paxlovid (updated)
nirmatrelvir, ritonavir, COVID-19 virus infection
Date of authorisation: 28/01/2022,
, Revision: 8, Authorised, Last updated: 25/01/2023
-
List item
Human medicine European public assessment report (EPAR): Ritonavir Mylan
ritonavir, HIV Infections
Date of authorisation: 09/11/2017,
, Revision: 13, Authorised, Last updated: 12/10/2022
-
List item
Human medicine European public assessment report (EPAR): Norvir
ritonavir, HIV Infections
Date of authorisation: 25/08/1996, Revision: 68, Authorised, Last updated: 18/10/2022 -
List item
Human medicine European public assessment report (EPAR): Opatanol
olopatadine hydrochloride, Conjunctivitis, Allergic
Date of authorisation: 16/05/2002, Revision: 23, Authorised, Last updated: 24/08/2022 -
List item
Human medicine European public assessment report (EPAR): Desloratadine ratiopharm
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 13/01/2012,, Revision: 12, Authorised, Last updated: 24/06/2022
-
List item
Human medicine European public assessment report (EPAR): Desloratadine Teva
desloratadine, Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal
Date of authorisation: 24/11/2011,, Revision: 18, Authorised, Last updated: 09/06/2022
-
List item
Human medicine European public assessment report (EPAR): Desloratadine Actavis
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 13/01/2012,, Revision: 15, Authorised, Last updated: 09/06/2022
-
List item
Human medicine European public assessment report (EPAR): Dasselta
desloratadine, Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria
Date of authorisation: 28/11/2011,, Revision: 13, Authorised, Last updated: 09/06/2022
-
List item
Human medicine European public assessment report (EPAR): Xolair (updated)
omalizumab, Asthma; Urticaria
Date of authorisation: 25/10/2005, Revision: 44, Authorised, Last updated: 01/02/2023 -
List item
Human medicine European public assessment report (EPAR): Dimethyl fumarate Mylan
dimethyl fumarate, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/05/2022,, Revision: 3, Authorised, Last updated: 12/12/2022
-
List item
Human medicine European public assessment report (EPAR): Ravicti
glycerol phenylbutyrate, Urea Cycle Disorders, Inborn
Date of authorisation: 26/11/2015,
, Revision: 15, Authorised, Last updated: 20/10/2022
-
List item
Human medicine European public assessment report (EPAR): Revinty Ellipta (updated)
fluticasone furoate, vilanterol trifenatate, Asthma
Date of authorisation: 02/05/2014, Revision: 21, Authorised, Last updated: 02/02/2023 -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2012
CHMP, Last updated: 19/10/2012Marketing-authorisation applicant Loraxin loratadine Vitabalans Oy … -
List item
Human medicine European public assessment report (EPAR): Xenpozyme
Olipudase alfa, Acid sphingomyelinase deficiency (ASMD) type A/B or type B
Date of authorisation: 24/06/2022,
, , Authorised, Last updated: 27/07/2022